^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DA-4505

    i
    Other names: DA-4505
    Associations

    News

    Trials
    Company:
    Dong-A
    Drug class:
    AHR antagonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=125, Recruiting, Dong-A ST Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Apr 2030 --> Oct 2029
    Enrollment open • Trial completion date
    |
    Keytruda (pembrolizumab) • DA-4505
    over2years
    Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=125, Not yet recruiting, Dong-A ST Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • DA-4505
    over3years
    A novel AhR inhibitor ‘DA-4505’ improved the anti-cancer efficacy of surgical and chemotherapy via synergistic anti-tumor effects of aPD-1 (AACR 2023)
    Here, we propose that a best-in-class AhR inhibitor, DA-4505, improves anti-tumor efficacy via modulation of tumor immune surveillance compared to BAY2416964, an AHR antagonist drug candidate being studied in the clinical phase. To evaluate anti-tumor effects of DA-4505 and BAY2416964, the two AhR inhibitors were dosed at 10 mg/kg once daily alone or in combination with aPD-1 (10 mg/kg) in surgical and chemotherapy models, and a PDX model (YHIM2004)...A tumor reduction was shown by treating DA-4505 alone or in combination with pembrolizumab compared to vehicle group (P<0.05)... The AhR inhibitor DA-4505 demonstrated an improvement in anti-tumor efficacy. In addition, it has shown a synergistic effect when combined with aPD-1. Discoveries from this study provide a preclinical rationale for future clinical implications in solid tumor.
    Clinical
    |
    CD8 (cluster of differentiation 8) • CCL8 (C-C Motif Chemokine Ligand 8) • CCL7 (Chemokine (C-C motif) ligand 7)
    |
    CCL7 expression
    |
    Keytruda (pembrolizumab) • DA-4505 • ilantimod (BAY 2416964)